Hympavzi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Marstacimab

Indications/Uses

Routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults & paed patients ≥12 yr w/ severe haemophilia A (congenital factor VIII deficiency) w/o factor VIII inhibitors or severe haemophilia B (congenital factor IX deficiency) w/o factor IX inhibitors.

Dosage/Direction for Use

SC Patient ≥12 yr weighing at least 35 kg Initially 300 mg loading dose followed by 150 mg once wkly.

Contraindications

Hypersensitivity.

MIMS Class

Haemostatics

ATC Classification

B02BX11 - marstacimab ; Belongs to the class of other systemic hemostatics. Used in the treatment of hemorrhage.

Regulatory Classification

POM

Presentation/Packing

Form

Hympavzi soln for inj 150 mg/mL

Packing/Price

1's

Hympavzi

Manufacturer:

Pfizer